GLP-1 Drugs and Your Health Plan: Managing the Ozempic Cost Crisis in 2026

GLP-1 utilization can materially affect some plans, but plan impact should be established from the employer’s own validated claims and pharmacy-contract data. No client-specific result is presented here because the cited example has not completed substantiation and permission review.

If you run an employer health plan in 2026, there’s a good chance GLP-1 drugs are already your most expensive line item — or they’re about to be. This story is playing out across West Michigan and nationally, and the math deserves a straight conversation — not a sales pitch.

Here’s what you need to know, what your options are, and how to make a smart decision for your plan and your people.

The Numbers That Matter

GLP-1 net plan cost varies by drug, indication, dose, contract, rebate treatment, and date. Treatment duration and outcomes after discontinuation vary by patient and should be discussed with a qualified clinician; trial-level average findings are not a universal patient outcome.

The scale of the problem:

• 49% of large employers now cover GLP-1s for weight management, not just diabetes, according to Mercer’s survey on health and benefits strategies.
• 34.2 million employer-insured individuals are medically eligible for these drugs.
• The potential premium impact is 5.3% to 13.8%, depending on uptake, per a Blue Cross Blue Shield analysis.
• BCBS of Massachusetts dropped GLP-1 coverage for weight management entirely in April 2025.

That last point matters. When a major Blue Cross plan walks away from coverage, it’s a signal that even large insurers are struggling with the math.

Why Small Groups Get Hit Harder

In a fully insured small group plan, one or two members on GLP-1 drugs move the needle on your entire renewal. Insurance pools risk, and in a pool of 20 employees, a $9,000-per-year drug claim isn’t diluted the way it is in a pool of 2,000.

Small group carriers in Michigan are pricing this into their trend assumptions. That 11.1% average rate increase for small groups? GLP-1 utilization is baked in.

Priority Health and Blue Cross Blue Shield of Michigan are both tightening prior authorization requirements and formulary placement for GLP-1s. They’re trying to manage the cost pressure without excluding coverage entirely — for now.

The challenge for small employers is fewer levers to pull. You can’t carve out your pharmacy benefit or negotiate directly with a PBM. But you do have options.

What Mid-Market Employers Should Do Right Now

If you’re self-funded or level-funded with 50 or more employees, you have more tools. Start here:

Audit your PBM contract. Your pharmacy benefit manager’s formulary and rebate structure determine what you actually pay. Some PBMs earn significant spread on GLP-1 medications. Ask for a transparent breakdown of net cost versus what the PBM charges your plan.

Lock down prior authorization criteria. Prior authorization is the most effective cost management tool for GLP-1s. Require documented BMI thresholds, evidence of comorbidities, and physician oversight before approving coverage for weight management. Thirty-four percent of employers already require participation in a lifestyle modification program alongside GLP-1 use.

Explore direct purchasing. Compounding pharmacies and direct-to-employer programs offer lower-cost alternatives. The legal landscape is shifting — FDA patent and exclusivity rules matter — but for some employers, these channels deliver meaningful savings.

Check your stop-loss coverage. If you’re self-funded, verify whether your stop-loss carrier added GLP-1 exclusions or lasering provisions. Some carriers treat high-cost GLP-1 users like hemophilia or gene therapy patients. Know your exposure.

Your Four Options

Every employer covering a health plan makes one of four choices on GLP-1s, whether they realize it or not:

Option 1: Cover GLP-1s Broadly

Cover them for both diabetes and weight management with standard prior authorization. This acknowledges the clinical evidence and keeps employees happy. It’s also the most expensive. If you choose this, budget for it explicitly and monitor utilization monthly.

Option 2: Cover for Diabetes Only

Limit GLP-1 coverage to FDA-approved diabetes indications. This is defensible and reduces cost exposure significantly. The trade-off: employees who would benefit from weight management use either pay out of pocket or go without.

Option 3: Cover with Clinical Guardrails

Cover GLP-1s for weight management, but require prior authorization, BMI thresholds, comorbidity documentation, and participation in a lifestyle program. This is the middle path where most thoughtful employers land. It controls costs while offering access.

Option 4: Exclude Entirely

Remove GLP-1s for weight management from your formulary. BCBS Massachusetts did this. It’s the cheapest option and legally permissible. But it’s a retention risk in a tight labor market, and may push costs to other parts of the system if obesity-related conditions go untreated.

No right answer exists for every employer. The right answer depends on your budget, workforce demographics, risk tolerance, and benefits philosophy.

The Clinical Reality Behind the Hype

GLP-1 drugs were developed for Type 2 diabetes. They work by mimicking a hormone that regulates blood sugar, slows stomach emptying, and reduces appetite. The weight loss results have been significant enough to make these the most talked-about medications in a generation.

The clinical results are real. Patients lose 15-20% of body weight on average, with measurable improvements in cardiovascular risk, blood pressure, and A1C levels. The KFF employer perspectives report documents both the clinical benefits and the cost challenges.

But here’s what often gets left out of the conversation: these drugs work best when paired with dietary changes, exercise, and behavioral support. Without those foundations, patients who stop the medication regain weight.

The Lifestyle Program Requirement

Thirty-four percent of employers that cover GLP-1s for weight management now require participation in a lifestyle modification program alongside the medication. This isn’t just cost control — it’s clinically sound.

A lifestyle program requirement protects both the employer’s investment and the employee’s long-term health. The Peterson-KFF Health System Tracker provides detailed data on how employers structure these clinical guardrails.

Options range from digital programs (Virta, Noom, Omada) that cost $200-400 per participant per year to onsite wellness coaching. For small employers, a simple requirement that the prescribing physician document a nutrition and exercise plan may be sufficient.

What to Do Before Your Next Renewal

Regardless of your size or funding model, take these steps before your next plan year:

Pull your pharmacy data. Ask your carrier, TPA, or PBM for a report on GLP-1 utilization and spend. Know your current exposure. Most employers are flying blind on this number.

Review your formulary. Understand where GLP-1 drugs sit on your formulary tiers and what your plan document says about weight management drug coverage. Many plan documents are ambiguous on this point.

Model the scenarios. What does your cost look like if utilization doubles? Triples? Don’t assume current utilization is the ceiling. It’s not.

Decide your philosophy. Have an intentional conversation with your leadership team about whether and how to cover these drugs. A default decision is still a decision — just one you didn’t think through.

Talk to your advisor. This is exactly where an independent advisor earns their keep. A good advisor will model the financial impact, benchmark your approach against similar employers, and help you make a decision you can defend to your board, employees, and budget.

Where the Advice Usually Falls Short

The conversation around GLP-1s tends to fall into two camps: dismiss them as a fad (wrong) or assume you have to cover them broadly (also wrong). Neither approach helps you make an informed decision.

The dismiss-as-fad crowd points to high costs and questions about long-term adherence. They’re missing the clinical pipeline of next-generation formulations, oral versions, and combination therapies. The eligible population is enormous. This cost pressure will intensify, not subside.

The cover-everything crowd focuses on employee satisfaction and clinical benefits while glossing over the budget impact. They’re not wrong about the benefits, but they’re not helping you manage the financial reality.

What’s actually needed is the hard work of analyzing your specific situation and building a defensible strategy.

The West Michigan Reality

Priority Health and BCBSM are both adjusting their approach to GLP-1 coverage for 2026. Priority Health tightened prior authorization requirements in January 2026. BCBSM moved several GLP-1 drugs to higher formulary tiers, increasing member cost-sharing.

For West Michigan employers, this means your fully insured options may be more restrictive than they were in 2025. If you want broader coverage, you may need to move to self-funding sooner than you planned.

The good news: Michigan has a strong independent advisor community and competitive PBM market. You have options if you know where to look.

The Bottom Line

GLP-1 drugs are not going away. The clinical evidence is solid. The eligible population is massive. The cost impact is real.

The employers who manage this well will be the ones who make deliberate, informed decisions now — not the ones who discover at renewal that their pharmacy spend increased 40% and nobody saw it coming.

You need someone who will walk through the math, benchmark your options, and help you build a strategy you can defend — not sell you on a carrier’s approach or duck the conversation entirely.

Nexus Benefit Solutions is an independent employee benefits advisory firm based in West Michigan. We help employers of all sizes navigate complex benefits decisions with data, not sales pitches. Our advisors will take the time to discuss your situation in detail. Schedule a call — no pitch, just clarity.

Internal Linking Suggestions: - Link to cost containment strategies post (Post #20) - Link to Michigan benchmarking post (Post #8) - Link to how to read your renewal post (Post #24) - Link to PBM reform post (Post #14)

Clinical sources and scope: Review current FDA prescribing information and the STEP 1 trial extension indexed by PubMed. These sources do not establish a universal treatment duration, outcome, or employer net cost.